Rxcurve
HCPCS J0895 · per 500 MG

Deferoxamine mesylate inj

Products billed under this code include Deferoxamine Mesylate, Desferal.

Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0895

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Deferoxamine Mesylate Pfizer Inc 00409-2337-25 16 $140.432
Deferoxamine Mesylate Apotex Corp 60505-6236-06 4 $35.108
Deferoxamine Mesylate Apotex Corp 60505-6238-06 4 $35.108
Deferoxamine Mesylate FreseniUS Kabi USA, LLC 63323-0597-10 1 $8.777
Deferoxamine Mesylate FreseniUS Kabi USA, LLC 63323-0599-30 4 $35.108
Desferal Novartis Pharmaceuticals Corporation 00078-0467-91 4 $35.108

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $8.777 −$1.243 500 MG Deferoxamine mesylate inj v1, posted September 17, 2026
3Q26 $10.02 +$1.443 500 MG Deferoxamine mesylate inj v1, posted September 15, 2026
2Q26 $8.577 +$0.109 500 MG Deferoxamine mesylate inj v1, posted September 15, 2026
1Q26 $8.468 −$0.541 500 MG Deferoxamine mesylate inj v1, posted September 15, 2026
4Q25 $9.009 −$0.007 500 MG Deferoxamine mesylate inj v1, posted September 8, 2026
3Q25 $9.016 +$0.808 500 MG Deferoxamine mesylate inj v1, posted March 10, 2026
2Q25 $8.208 −$0.729 500 MG Deferoxamine mesylate inj v1, posted March 10, 2026
1Q25 $8.937 +$2.159 500 MG Deferoxamine mesylate inj v1, posted December 19, 2025
4Q24 $6.778 −$0.122 500 MG Deferoxamine mesylate inj v1, posted June 11, 2025
3Q24 $6.90 −$2.121 500 MG Deferoxamine mesylate inj v1, posted June 11, 2025
2Q24 $9.021 +$0.424 500 MG Deferoxamine mesylate inj v1, posted March 11, 2025
1Q24 $8.597 +$0.006 500 MG Deferoxamine mesylate inj v1, posted December 19, 2024
4Q23 $8.591 −$0.001 500 MG Deferoxamine mesylate inj v1, posted October 10, 2024
3Q23 $8.592 +$0.377 500 MG Deferoxamine mesylate inj v1, posted June 5, 2024
2Q23 $8.215 −$0.448 500 MG Deferoxamine mesylate inj v1, posted February 23, 2024
1Q23 $8.663 +$0.735 500 MG Deferoxamine mesylate inj v1, posted December 6, 2023
4Q22 $7.928 −$2.488 500 MG Deferoxamine mesylate inj v1, posted June 22, 2023
3Q22 $10.416 +$3.218 500 MG Deferoxamine mesylate inj v1, posted June 9, 2023
2Q22 $7.198 −$0.668 500 MG Deferoxamine mesylate inj v1, posted December 14, 2022
1Q22 $7.866 +$0.204 500 MG Deferoxamine mesylate inj v1, posted June 8, 2022
4Q21 $7.662 −$0.935 500 MG Deferoxamine mesylate inj v1, posted June 2, 2022
3Q21 $8.597 −$0.03 500 MG Deferoxamine mesylate inj v1, posted June 2, 2022
2Q21 $8.627 +$0.726 500 MG Deferoxamine mesylate inj v1, posted March 1, 2022
1Q21 $7.901 – 500 MG Deferoxamine mesylate inj v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files